183 related articles for article (PubMed ID: 18824122)
1. CB(1) receptor antagonism: biological basis for metabolic effects.
Di Marzo V
Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
3. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
Mach F; Montecucco F; Steffens S
Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
[TBL] [Abstract][Full Text] [Related]
4. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
5. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
6. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Dibble CT; Gelfand EV; Cannon CP
Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
[TBL] [Abstract][Full Text] [Related]
7. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
[TBL] [Abstract][Full Text] [Related]
8. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
9. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Bronander KA; Bloch MJ
Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
[TBL] [Abstract][Full Text] [Related]
10. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
Lafontan M; Piazza PV; Girard J
Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
[TBL] [Abstract][Full Text] [Related]
11. Rimonabant--a selective CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
[TBL] [Abstract][Full Text] [Related]
12. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.
Duffy D; Rader D
Trends Cardiovasc Med; 2007 Feb; 17(2):35-43. PubMed ID: 17292044
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
[TBL] [Abstract][Full Text] [Related]
16. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
18. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Gelfand EV; Cannon CP
J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
[TBL] [Abstract][Full Text] [Related]
19. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
20. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
